Abstract
Many perinatal characteristics are associated with risk for pediatric asthma. Identification of biologic processes influenced by these characteristics could facilitate risk stratification or new therapeutic targets. Using publicly available transcriptomic data from CBMCs, transcription of genes involved in myeloid differentiation were inversely associated with pediatric asthma risk stratification based on gestational age at birth, sex, birthweight, and maternal pre-pregnancy BMI. This gene signature was validated in an independent cohort and was specifically associated with genes localizing to neutrophil specific granules. Changes in these genes correlated with changes in protein abundance in serum. CBMC serum levels of PGLYRP-1, a specific granule protein, and sIL6Rα, a membrane protein, were tested for association with pulmonary outcomes. PGLYRP-1 concentration was inversely associated with mid-childhood current asthma and early-teen FEV1/FVC×100. Thus, variation in neutrophil specific granule abundance at birth is associated with individual risk for pediatric asthma and reduced pulmonary function in adolescence.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02820402
Funding Statement
This work was funded by the National Institutes of Health, grant nos. R01 AI 053878, F30 HL 136001, R01 HD 034568, and UH3 OD 023286, the Robert Wood Johnson Foundation Nurse Faculty Scholars Program 72117, the College of Nursing Deans Award, and University of Illinois at Chicago Department of Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The current study was approved by the University of Illinois at Chicago IRB, 20160326 and 20150353, and the IRB of Harvard Pilgrim Health Care.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was funded by the National Institutes of Health [grant nos. R01 AI 053878, F30 HL 136001, R01 HD 034568, and UH3 OD 023286], the Robert Wood Johnson Foundation [Nurse Faculty Scholars Program #72117], the College of Nursing Dean’s Award, and University of Illinois at Chicago Department of Medicine.
Competing Interests: The authors declare that they have no relevant conflicts of interest.
Data Availability
Data from RNAseq is available on NCBI SRA database ID PRJNA577955.
